| 1 |
Antimicrobial susceptibility of Treponema pallidum subspecies pallidum: an in-vitro study
Lauren C. Tantalo, Nicole A. P. Lieberman, Clara Pérez‐Mañá et al. · The Lancet Microbe
Open access |
9 Oct 2023 |
60 |
| 2 |
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii
Samir H. Moussa, Adam B. Shapiro, Sarah M. McLeod et al. · Antimicrobial Agents and Chemotherapy
Open access |
16 Oct 2023 |
51 |
| 3 |
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
Alison Luckey et al. · The Lancet
Open access |
11 Dec 2025 |
45 |
| 4 |
ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock
Daniel E. Leisman, Damian R. Handisides, Laurence W. Busse et al. · Critical Care
Open access |
18 Apr 2024 |
36 |
| 5 |
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock
Daniel E. Leisman, Damian R. Handisides, Lakhmir S. Chawla et al. · Annals of Intensive Care
Open access |
2023 |
23 |
| 6 |
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)
Alita A. Miller, Samir H. Moussa, Sarah M. McLeod · Antimicrobial Agents and Chemotherapy
Open access |
3 Apr 2024 |
18 |
| 7 |
An index of the initial blood pressure response to angiotensin II treatment and its association with clinical outcomes in vasodilatory shock
Daniel E. Leisman, Patrick M. Wieruszewski, Laurence W. Busse et al. · Critical Care
Open access |
19 Feb 2025 |
16 |
| 8 |
In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam
Mollie VanNatta, Laurie Grier, Muhammad Hamid Khan et al. · Open Forum Infectious Diseases
Open access |
30 Sep 2023 |
16 |
| 9 |
Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests
Sarah M. McLeod, Nicole Carter, Michael D. Huband et al. · Journal of Clinical Microbiology
Open access |
14 Dec 2023 |
10 |
| 10 |
The XRISM science data center: optimizing the scientific return from a unique x-ray observatory
Michael Loewenstein et al.
Conference paper |
12 Dec 2020 |
10 |
| 11 |
Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae from the microbiological failures in the international, zoliflodacin, phase 3, clinical trial for treatment of uncomplicated urogenital gonorrhoea: a retrospective, genomic, observational study
Magnus Unemo, Daniel Golparian, Varalakshmi Elango et al. · The Lancet Microbe
Open access |
Feb 2026 |
6 |
| 12 |
Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations
Yasmeen Abouelhassan, Yuwei Shen, April Chen et al. · Antimicrobial Agents and Chemotherapy
Open access |
10 Dec 2024 |
6 |
| 13 |
Critical care clinical pharmacy value-based metrics: Time to terminate widget counting
Mitchell S. Buckley, Russel Joseph Roberts · American Journal of Health-System Pharmacy
|
7 Jun 2024 |
5 |
| 14 |
Vasoactive Agents in Burn Patients: Perspectives on Angiotensin-II
Scott W. Mueller, Nicolas Tran, Kevin D. Betthauser et al. · Journal of Burn Care & Research
Open access |
11 Dec 2024 |
3 |
| 15 |
EXaminaTion of cRitical cAre PHArmacist pRoductivity MetricS ( EXTRA ‐ PHARMS ): The clinical pharmacist's perspective
Christy Cecil Forehand et al. · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
|
30 Oct 2024 |
2 |
| 16 |
Inference of ceftobiprole susceptibility through surrogate testing of ceftaroline
Hs Sader, Rodrigo E. Mendes, David P. Nicolau et al. · Journal of Clinical Microbiology
Open access |
24 Feb 2026 |
1 |
| 17 |
P-1532. Surveillance of Eravacycline Against Clinical Pathogens, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2018-2022
Stephen Hawser, Federica Monti, Sherry Siegert et al. · Open Forum Infectious Diseases
Open access |
29 Jan 2025 |
1 |
| 18 |
2138. In Vitro Susceptibility of Recent Clinical Isolates of P. aeruginosa and Enterobacterales to Imipenem or Meropenem Alone or in Combination with Sulbactam-Durlobactam
Sarah M. McLeod, Nicole Carter, Samir H. Moussa et al. · Open Forum Infectious Diseases
Open access |
27 Nov 2023 |
1 |
| 19 |
2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function
Kajal B. Larson, Sujata M. Bhavnani, Jeffrey Hammel et al. · Open Forum Infectious Diseases
Open access |
27 Nov 2023 |
1 |
| 20 |
XSLIDE (x-ray spectral line identifier and explorer): a quick-look tool for XRISM
Efrem Braun, Chris Baluta, Trisha F. Doyle et al. · Space Telescopes and Instrumentation 2022: Ultraviolet to Gamma Ray
Conference paperOpen access |
21 Jul 2022 |
1 |
| 21 |
Zoliflodacin: non-inferior, but not equivalent? – Authors’ reply
Alison Luckey, Manica Balasegaram, Drew Lewis et al. · The Lancet
|
May 2026 |
0 |
| 22 |
878: THROMBOEMBOLIC EVENTS IN THE ANGIOTENSIN II FOR THE TREATMENT OF HIGH-OUTPUT SHOCK PHASE 3 TRIAL
Patrick Wieruszewski, Rebecca Caragata, Adham Mohamed et al. · Critical Care Medicine
|
Mar 2026 |
0 |
| 23 |
570. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Continuous Infusion Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
Sujata M. Bhavnani, Jeffrey Hammel, Christopher M. Rubino et al. · Open Forum Infectious Diseases
Open access |
2026 |
0 |
| 24 |
P-1206. Association of Sex Assigned at Birth and Sexual Orientation with Antimicrobial Susceptibility of Baseline Neisseria gonorrhoeae Isolates from Participants Recruited in the Global Zoliflodacin Phase 3 Randomized Controlled Trial
Sarah M. McLeod, Esther Bettiol, Varalakshmi Elango et al. · Open Forum Infectious Diseases
Open access |
2026 |
0 |
| 25 |
Humanizing Critical Care: Transforming ICUs Through Empathy and Innovation
Asad Iqbal Mian, Muhammad Taha Anver, Mahreen Sulaiman et al. · ConductScience Journal
Open access |
2 Sep 2025 |
0 |
| 26 |
Evaluating Pediatric Healthcare Spaces: Evidence-Based Recommendations for Design and Engagement
Asad Iqbal Mian, Muhammad Taha Anver, Mahreen Sulaiman et al. · ConductScience Journal
Open access |
22 Jul 2025 |
0 |
| 27 |
Transforming Emergency Care: Scalable Clinical Audit Innovations for Emerging Markets
Asad Iqbal Mian, Muhammad Taha Anver, Mahreen Sulaiman et al. · ConductScience Journal
Open access |
22 Jul 2025 |
0 |
| 28 |
P-1578. Impact of a Pharmacist-Driven Carbapenem De-escalation Algorithm for Hospitalized Patients with Urinary Tract Infections
Timothy P. Gauthier, Susana Diaz, Kelsey N Williams et al. · Open Forum Infectious Diseases
Open access |
29 Jan 2025 |
0 |
| 29 |
Motivating Creativity - Creating Motivation
Maren Baermann · AIJR Proceedings
Conference paperOpen access |
18 Dec 2023 |
0 |
| 30 |
2132. Surveillance of Eravacycline Against Enterobacterales and Non-Fermenter Clinical Isolates, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2021
Stephen Hawser, Nimmi Kothari, Federica Monti et al. · Open Forum Infectious Diseases
Open access |
27 Nov 2023 |
0 |
| 31 |
2133. Surveillance of Eravacycline Against Gram-positive Clinical Pathogens, Including Resistant Isolates, Collected Worldwide From Multiple Infection Sites During 2021
Stephen Hawser, Nimmi Kothari, Federica Monti et al. · Open Forum Infectious Diseases
Open access |
27 Nov 2023 |
0 |
| 32 |
85. Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in a Phase 3 Trial
Alita A. Miller, Sarah M. McLeod, Adam B. Shapiro et al. · Open Forum Infectious Diseases
Open access |
27 Nov 2023 |
0 |
| 33 |
The XRISM pipeline software system: connecting continents, processes, testing, and scientists
Trisha F. Doyle, Matthew Holland, Robert Sean Hill et al. · Space Telescopes and Instrumentation 2022: Ultraviolet to Gamma Ray
Conference paperOpen access |
21 Jul 2022 |
0 |